Answers are grounded in this paper and cite their sources.
Early diagnosis and immunosuppressive treatment are crucial for improving the clinical course and survival of patients with giant cell myocarditis.
Giant cell myocarditis (GCM) is a rare, rapidly progressive and highly lethal disease in young and middle-aged adults. It is attributed to an inflammation of the heart muscle, and mediated by T lymphocytes and anti-myosin autoantibodies. Making diagnosis of GCM with multiple noninvasive imaging modalities is possible in a small percentage of patients, so myocardial tissue diagnosis is often required. An early diagnosis is very important, because immunosuppressive treatment may significantly improve clinical course and survival of these patients. GCM often escapes diagnosis until autopsy or transplantation and has defied proper treatment trials for its rarity and deadly behavior. This review will focus on the diagnostic approach to patients with suspected GCM and currently evidence-based treatment strategy for this disease.
No takes yet. Share an insight, caveat, or question.
Veia et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: